Thu, Sep 18, 2014, 9:54 AM EDT - U.S. Markets close in 6 hrs 6 mins

Recent

% | $
Quotes you view appear here for quick access.

pSivida Corp. Message Board

  • liberal_nation liberal_nation Feb 1, 2013 4:19 PM Flag

    Since You Asked

     

    PSDV is a good company with a fairly good track record of success.
    I played the Iluvien run-up going into the November 2011 CRL.
    Management does not seem upbeat about approval without the
    additional phase III trials "requested" by the FDA. It is folly to believe
    that the FDA is inclined to approve just because they accepted the NDA
    for review. Just take a look at the four CRLs DSCO's Surfaxin received
    before finally gaining approval. Then, there's dear old HEB. How many
    times has Ampligen received a CRL. The drug has been around since
    the 1960's. It's been applied to every trendy malady to come along from
    HIV to Chronic Fatigue Syndrome, and still no approval. Ampligen has
    a PDUFA of February 2nd. It will be yet another CRL. I just dropped by
    to see what was moving the stock. It's on one of my watch lists.
    I hope the reformatted data will win over the FDA, but, in my experience,
    that rarely happens.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • godwintom@att.net godwintom Feb 1, 2013 4:54 PM Flag

      Thanks, for your reply but it indicates to me that you play the whats hot stuff that doesnt take much research into whats going on within a company. You mentioned nothing about what PSDV has in the pipeline which is the strongest indicator that small bios can have in most cases.So in plain language,
      your lack of knowledge is revealed through your willingness to quickly demean other people and throw down a smoke screen about whats already happened. I think the call that (old news) We welcome you to this board but bring something constructive.

 
PSDV
4.19+0.13(+3.20%)9:53 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.